Special Issue "Guidelines, New Data and Real-World Evidence with Oral Anticoagulants"
Deadline for manuscript submissions: 31 December 2021.
Interests: oral anticoagulants (OAC); atrial fibrillation; acute coronary syndrome; percutaneous coronary intervention (PCI); guidelines
Special Issues and Collections in MDPI journals
There has been considerable progress in the pharmacology of oral anticoagulants (OAC) over the last twenty years, and non-vitamin K antagonists OAC (NOAC) have dramatically changed clinical practice. NOAC have demonstrated a favorable risk–benefit profile in patients with atrial fibrillation and with venous thromboembolism in phase III trials, although real-world evidence highlights that several issues in the implementation of NOAC in clinical practice still remain unresolved in specific subsets. On the other hand, re-emerging concepts on the pathophysiology of atherothrombosis have paved the way for a new therapeutic option consisting in the association of antiplatelet and low-dose NOAC, known as dual pathway inhibition. While guidelines issued by scientific societies summarize and evaluate available evidence to facilitate clinicians in their decision making for daily practice, continuously evolving research introduces new diagnostic algorithms and challenges therapeutic concepts. The present Special Issue has been thought to provide an overview of the latest evidence in the field of OAC focusing on both diagnostic and therapeutic advances and highlighting their implications for patients’ prognosis. Therefore, we welcome the submission of review articles as well as original research papers dealing with the topics of guidelines, new data, and real-world evidence about OAC in atrial fibrillation, atherothrombosis, and venous thromboembolism.
Dr. Giuseppe Andò
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- oral anticoagulants (OAC)
- atrial fibrillation
- venous thromboembolism (VTE)
- dual pathway inhibition (DPI)
- coronary artery disease (CAD)
- peripheral artery disease (PAD)
- real-world evidence (RWE)